acute respiratory distresssyndrome,ARDS
Conditions
Interventions
Hydrogen and oxygen mixture treatment group:Hydrogen and oxygen mixture treatment group
countrol group:oxygen treatment
Sponsors
Lianyungang First People's Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 80 years, inclusive; no gender limitation; 2. Within one week of onset, there are known clinical manifestations of impaired respiratory system or new/aggravated respiratory symptoms; 3. Chest imaging shows that the light transmittance of both lungs is weakened, which cannot be fully explained by pleural effusion, lobar pneumonia, atelectasis, pulmonary nodules, etc.; 4. Respiratory failure cannot be fully explained by heart failure or excessive fluid, except for pulmonary edema caused by increased hydrostatic pressure; 5. Blood gas analysis: P/F <= 300 mmHg; 6. Mechanical ventilation therapy (invasive or non-invasive); 7. The patient or the legal representative signs the informed consent.
Exclusion criteria
Exclusion criteria: 1. Women during pregnancy or lactation; 2. The expected survival time of patients due to underlying diseases is less than 28 days, such as terminal malignant tumors, cardiac arrest within 30 days before enrollment, and terminal lung disease; 3. The patient has the following chronic organ dysfunction or immunosuppression (according to the chronic health score assessment of APACHE II score): (1) Heart: Heart function class IV of the New York Heart Association; (2) Respiration: Chronic obstructive, obstructive or vascular pulmonary disease causes severe limitation of usual activities, that is, unable to go upstairs or unable to do housework; or clear chronic hypoxia, CO2 retention, secondary polycythemia vera, severe Pulmonary hypertension (> 40 mmHg) or ventilator dependence; (3) Kidney: receive long-term dialysis treatment; (4) Liver: biopsy confirmed liver cirrhosis and clear portal hypertension; previous upper gastrointestinal bleeding caused by portal hypertension; or previous liver failure/hepatic encephalopathy/hepatic coma; (5) Immune function suppression: The received treatment measures affect the resistance to infection (such as immunosuppressive therapy, chemotherapy, radiotherapy, long-term or short-term use of high-dose hormones), or the disease affects the resistance to infection (such as leukemia, lymphoma and AIDS) (6) Solid organ or bone marrow transplantation; (7) Plant survival status; 4. The following situations occurred within 4 weeks before enrollment: (1) Acute pulmonary embolism; (2) Blood transfusion reaction; (3) Acute coronary syndrome; 5. The patient and/or the legal representative sign the Do Not Rescue (DNR), or decide to withdraw the life support treatment (withdraw) or limit the life support treatment intensity (withhold) and sign the relevant informed consent; 6. Patients who are considered unsuitable to participate in this trial by the attending doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mechanical power;Lung compliance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Days of survive within 28 days;No mechanical ventilation days within 28 days;Trend of RALE score and LUS score level at 0, 3 and 7 days after treatment;Trend of inflammatory cytokines IL-6 and IL-10 levels at 0, 3 and 7 days after treatment; | — |
Countries
China
Contacts
Public ContactLi Xiaomin
Lianyungang First People's Hospital
Outcome results
None listed